Posted by Michael Wonder on 23 Oct 2023
MHRA authorises bispecific antibody therapy Tepkinly as a treatment for diffuse large B-cell lymphoma in adults
20 October 2023 - Patients with recurring lymphoma, or who have not responded to prior treatments, could access a new bispecific antibody therapy to help treat their condition.
The MHRA has today authorised a new medicine called Tepkinly (epcoritamab), a treatment for diffuse large B-cell lymphoma in adults.
